ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 132 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $422,000 | -67.7% | 9,156 | -41.1% | 0.00% | -100.0% |
Q4 2021 | $1,306,000 | +45.0% | 15,539 | +14.9% | 0.00% | 0.0% |
Q3 2021 | $901,000 | +21.4% | 13,525 | -3.0% | 0.00% | – |
Q2 2021 | $742,000 | +89.8% | 13,938 | +54.6% | 0.00% | – |
Q1 2021 | $391,000 | – | 9,015 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |